UNLABELLED: We evaluated the ability of the PET imaging agent (89)Zr-trastuzumab to delineate HER2-positive gastric cancer and to monitor the pharmacodynamic effects of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor afatinib. METHODS: Using (89)Zr-trastuzumab, (18)F-FDG, or 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLT PET), we imaged HER2-positive NCI-N87 and HER2-negative MKN74 gastric cancer xenografts in mice. Next, we examined the pharmacodynamic effects of afatinib in NCI-N87 xenografts using (89)Zr-trastuzumab and (18)F-FDG PET and comparing imaging results to changes in tumor size and in protein expression as monitored by Western blot and histologic studies. RESULTS: Although (18)F-FDG uptake in NCI-N87 tumors did not change, a decrease in (89)Zr-trastuzumab uptake was observed in the afatinib-treated versus control groups (3.0 ± 0.0 percentage injected dose per gram (%ID/g) vs. 21.0 ± 3.4 %ID/g, respectively; P < 0.05). (89)Zr-trastuzumab PET results corresponded with tumor reduction, apoptosis, and downregulation of HER2 observed on treatment with afatinib. Downregulation of total HER2, phosphorylated (p)-HER2, and p-EGFR occurred within 24 h of the first dose of afatinib, with a sustained effect over 21 d of treatment. CONCLUSION: Afatinib demonstrated antitumor activity in HER2-positive gastric cancer in vivo. (89)Zr-trastuzumab PET specifically delineated HER2-positive gastric cancer and can be used to measure the pharmacodynamic effects of afatinib.
UNLABELLED: We evaluated the ability of the PET imaging agent (89)Zr-trastuzumab to delineate HER2-positive gastric cancer and to monitor the pharmacodynamic effects of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitor afatinib. METHODS: Using (89)Zr-trastuzumab, (18)F-FDG, or 3'-deoxy-3'-(18)F-fluorothymidine ((18)F-FLTPET), we imaged HER2-positive NCI-N87 and HER2-negative MKN74 gastric cancer xenografts in mice. Next, we examined the pharmacodynamic effects of afatinib in NCI-N87 xenografts using (89)Zr-trastuzumab and (18)F-FDG PET and comparing imaging results to changes in tumor size and in protein expression as monitored by Western blot and histologic studies. RESULTS: Although (18)F-FDG uptake in NCI-N87 tumors did not change, a decrease in (89)Zr-trastuzumab uptake was observed in the afatinib-treated versus control groups (3.0 ± 0.0 percentage injected dose per gram (%ID/g) vs. 21.0 ± 3.4 %ID/g, respectively; P < 0.05). (89)Zr-trastuzumabPET results corresponded with tumor reduction, apoptosis, and downregulation of HER2 observed on treatment with afatinib. Downregulation of total HER2, phosphorylated (p)-HER2, and p-EGFR occurred within 24 h of the first dose of afatinib, with a sustained effect over 21 d of treatment. CONCLUSION:Afatinib demonstrated antitumor activity in HER2-positive gastric cancer in vivo. (89)Zr-trastuzumabPET specifically delineated HER2-positive gastric cancer and can be used to measure the pharmacodynamic effects of afatinib.
Entities:
Keywords:
18F-FDG; 89Zr-trastuzumab; HER2; afatinib; gastric cancer
Authors: Elisabeth G E de Vries; Thijs H Oude Munnink; Marcel A T M van Vugt; Wouter B Nagengast Journal: Cancer Discov Date: 2011-06-01 Impact factor: 39.397
Authors: W A Weber; K Ott; K Becker; H J Dittler; H Helmberger; N E Avril; G Meisetschläger; R Busch; J R Siewert; M Schwaiger; U Fink Journal: J Clin Oncol Date: 2001-06-15 Impact factor: 44.544
Authors: Brian Leyland-Jones; Ramon Colomer; Maureen E Trudeau; Andrew Wardley; Jean Latreille; David Cameron; Ricardo Cubedo; Nedal Al-Sakaff; Andrea Feyereislova; Olivier Catalani; Yumi Fukushima; Michael Brewster; Javier Cortés Journal: J Clin Oncol Date: 2009-12-21 Impact factor: 44.544
Authors: Wouter B Nagengast; Marjolijn N Lub-de Hooge; Sjoukje F Oosting; Wilfred F A den Dunnen; Frank-Jan Warnders; Adrienne H Brouwers; Johan R de Jong; Patricia M Price; Harry Hollema; Geke A P Hospers; Philip H Elsinga; Jan Willem Hesselink; Jourik A Gietema; Elisabeth G E de Vries Journal: Cancer Res Date: 2010-11-17 Impact factor: 12.701
Authors: J De Grève; E Teugels; C Geers; L Decoster; D Galdermans; J De Mey; H Everaert; I Umelo; P In't Veld; D Schallier Journal: Lung Cancer Date: 2012-02-10 Impact factor: 5.705
Authors: Jason P Holland; Vadim Divilov; Neil H Bander; Peter M Smith-Jones; Steven M Larson; Jason S Lewis Journal: J Nucl Med Date: 2010-07-21 Impact factor: 10.057
Authors: Neil P Shah; Hagop M Kantarjian; Dong-Wook Kim; Delphine Réa; Pedro E Dorlhiac-Llacer; Jorge H Milone; Jorge Vela-Ojeda; Richard T Silver; H Jean Khoury; Aude Charbonnier; Nina Khoroshko; Ronald L Paquette; Michael Deininger; Robert H Collins; Irma Otero; Timothy Hughes; Eric Bleickardt; Lewis Strauss; Stephen Francis; Andreas Hochhaus Journal: J Clin Oncol Date: 2008-06-09 Impact factor: 44.544
Authors: Martin Schuler; Ahmad Awada; Philipp Harter; Jean Luc Canon; Kurt Possinger; Marcus Schmidt; Jacques De Grève; Patrick Neven; Luc Dirix; Walter Jonat; Matthias W Beckmann; Jochen Schütte; Peter A Fasching; Nina Gottschalk; Tatiana Besse-Hammer; Frank Fleischer; Sven Wind; Martina Uttenreuther-Fischer; Martine Piccart; Nadia Harbeck Journal: Breast Cancer Res Treat Date: 2012-07-05 Impact factor: 4.872
Authors: Joseph A O'Donoghue; Jason S Lewis; Neeta Pandit-Taskar; Stephen E Fleming; Heiko Schöder; Steven M Larson; Volkan Beylergil; Shutian Ruan; Serge K Lyashchenko; Pat B Zanzonico; Wolfgang A Weber; Jorge A Carrasquillo; Yelena Y Janjigian Journal: J Nucl Med Date: 2017-06-21 Impact factor: 10.057
Authors: Adriana V F Massicano; Supum Lee; Bryant K Crenshaw; Tolulope A Aweda; Retta El Sayed; Ian Super; Ron Bose; Bernadette V Marquez-Nostra; Suzanne E Lapi Journal: Cancer Biother Radiopharm Date: 2019-01-24 Impact factor: 3.099
Authors: Jorge A Carrasquillo; Maurizio Scaltriti; Nikolaus Schultz; Yelena Y Janjigian; Francisco Sanchez-Vega; Jaclyn F Hechtman; Pau Castel; Geoffrey Y Ku; Yaelle Tuvy; Helen Won; Christopher J Fong; Nancy Bouvier; Gouri J Nanjangud; Joanne Soong; Efsevia Vakiani; Mark Schattner; David P Kelsen; Robert A Lefkowitz; Karen Brown; Mario E Lacouture; Marinela Capanu; Marissa Mattar; Besnik Qeriqi; Fabiola Cecchi; Yuan Tian; Todd Hembrough; Rebecca J Nagy; Richard B Lanman; Steven M Larson; Neeta Pandit-Taskar; Heiko Schöder; Christine A Iacobuzio-Donahue; David H Ilson; Wolfgang A Weber; Michael F Berger; Elisa de Stanchina; Barry S Taylor; Jason S Lewis; David B Solit Journal: Cancer Discov Date: 2018-11-21 Impact factor: 39.397